Zidovudine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Zidovudine

Examples of brand names: Retrovir [DE]

ATC code: J05AF01

Main use (for orientation): HIV

Documented research summary

The CBD label reports measured zidovudine AUC +19%, Cmax +7% with CBD 7.5 mg/kg twice daily; assessed as not clinically significant. PBPK +30% with CBD 700 mg twice daily remains a separate prediction, not a patient result.

Uncertainties and limitations

Oral and intravenous single-ingredient RETROVIR zidovudine preparations; the CBD pair measurement concerns 300 mg orally.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinically studied

Finding ID: B0006

Type of result: Positive finding / indication

Observation: AUC +19%, Cmax +7%.

Mechanism: UGT2B7 probe

Study type: Human pharmacokinetics according to product information

Context studied: CBD 7.5 mg/kg twice daily; zidovudine 300 mg; n not stated.

Clinical interpretation: Expected to be low according to prescribing information

Limitations and uncertainties: Do not indiscriminately extrapolate to all UGT2B7 substrates. EU and US product information expect no clinically significant change under the investigated conditions. Keep the higher CBD regimen in the prediction separate.

Original sources for this finding: EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026 [V5_US_LABEL_2026]; EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025 [CL02]

CBD – theoretical plausibility

Finding ID: B0104

Type of result: Context-specific finding; read the limitations

Observation: AUC increase of 30% predicted.

Mechanism: UGT2B7 inhibition; PBPK

Study type: PBPK model based on in vitro data

Context studied: Model: repeated oral CBD 700 mg twice daily; zidovudine fraction metabolised 0.70.

Clinical interpretation: Clinical relevance unresolved

Limitations and uncertainties: Not an observed patient interaction; not azithromycin.

Original sources for this finding: Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations [ME04]

References and access status

[V2_LABEL_D0444] RETROVIR (ZIDOVUDINE) CAPSULE RETROVIR (ZIDOVUDINE) SOLUTION RETROVIR (ZIDOVUDINE) INJECTION, SOLUTION [VIIV HEALTHCARE COMPANY]

Original source / bibliographic reference

Authors: ViiV Healthcare Company

Year: 2024

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL02] EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025

Original source / bibliographic reference

Authors: FDA / Jazz Pharmaceuticals

Year: 2025

Source type: Regulatory product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[ME04] Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations

Original source / bibliographic reference

Authors: Bansal S; Paine MF; Unadkat JD

Year: 2025

Source type: Original study: in vitro UGT and PBPK

DOI: 10.1016/j.dmd.2025.100096

PMID: 40482431

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[V5_US_LABEL_2026] EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026

Original source / bibliographic reference

Authors: Jazz Pharmaceuticals, Inc. / DailyMed

Year: 2026

Source type: Regulatory US product information; not an additional independent clinical study

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility